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Abstract
Background: The aim of the present study was to investigate the efficacy of adjuvant dose-dense sequential chemotherapy
with epirubicin, paclitaxel, and CMF in subgroups of patients with high-risk operable breast cancer, according to tumor
subtypes defined by immunohistochemistry (IHC).
Materials and Methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 1,039 patients participating in
two adjuvant dose-dense sequential chemotherapy phase III trials were centrally assessed in tissue micro-arrays by IHC for 6
biological markers, that is, estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki67, cytokeratin 5 (CK5), and EGFR.
The majority of the cases were further evaluated for HER2 amplification by FISH. Patients were classified as: luminal A (ER/
PgR-positive, HER2-negative, Ki67
low); luminal B (ER/PgR-positive, HER2-negative, Ki67
high); luminal-HER2 (ER/PgR-positive,
HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); triple-negative (TNBC) (ER-negative, PgR-
negative, HER2-negative); and basal core phenotype (BCP) (TNBC, CK5-positive and/or EGFR-positive).
Results: After a median follow-up time of 105.4 months the 5-year disease-free survival (DFS) and overall survival (OS) rates
were 73.1% and 86.1%, respectively. Among patients with HER2-enriched tumors there was a significant benefit in both DFS
and OS (log-rank test; p=0.021 and p=0.006, respectively) for those treated with paclitaxel. The subtype classification was
found to be of both predictive and prognostic value. Setting luminal A as the referent category, the adjusted for prognostic
factors HR for relapse for patients with TNBC was 1.91 (95% CI: 1.31–2.80, Wald’s p=0.001) and for death 2.53 (95% CI: 1.62–
3.60, p,0.001). Site of and time to first relapse differed according to subtype. Locoregional relapses and brain metastases
were more frequent in patients with TNBC, while liver metastases were more often seen in patients with HER2-enriched
tumors.
Conclusions: Triple-negative phenotype is of adverse prognostic value for DFS and OS in patients treated with adjuvant
dose-dense sequential chemotherapy. In the pre-trastuzumab era, the HER2-enriched subtype predicts favorable outcome
following paclitaxel-containing treatment.
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Breast cancer is the most common female malignancy in the
USA accounting for 27% of all new cancer cases, although its
yearly incidence is declining since 1999 [1]. Anthracyclines
(doxorubicin and epirubicin) and taxanes (paclitaxel and doc-
etaxel) are the most commonly used chemotherapeutic agents in
the adjuvant treatment of ‘‘high-risk’’ breast cancer. The Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) recently
presented compelling data showing that taxane-based regimens
are superior to anthracycline-based regimens [2], even though
their superiority has been confronted by the results of the recently
published ‘‘Taxotere as Adjuvant Chemotherapy Trial’’ (TACT)
[3]. Consequently, the role of taxanes in the adjuvant setting
remains equivocal (reviewed in ref. [4]). It should be noted
however, that two recent meta-analyses of adjuvant chemotherapy
trials, with or without taxanes, have shown a clear taxane benefit
in high-risk early breast cancer patients [5,6]. The combination of
an anthracycline with a taxane seems therefore to be a logical step
forward in the treatment of early ‘‘high-risk’’ breast cancer, since
their mechanism of action is different and are not cross-resistant
[7–10]. However, their optimal sequence of administration, i.e.
concurrently or sequentially, and the role of dose intensity is not
well defined yet. The sequential approach may be more effective,
since it allows drugs to be given at full doses with less frequent dose
reductions, thus increasing dose intensity (DI). Nevertheless, in the
recently published Breast Cancer International Research Group-
005 (BCIRG-005) study the sequential administration of doxoru-
bicin and cyclophosphamide followed by docetaxel did not
improve the outcome of patients compared to the concurrent
administration of the three drugs [11].
Dose-dense chemotherapy (the increase of DI by reducing the
interval between cycles), with the use of granulocyte colony
stimulating factors (G-CSFs), is the result of the application of
mathematical models of cell growth kinetics into the clinical
practice [12]. This type of chemotherapy has been successfully
evaluated during the last 15 years in patients with operable breast
cancer (reviewed in [13–15]), even in those of older age [16].
Dose-dense sequential chemotherapeutic regimens are consid-
ered highly effective and better tolerated than conventional
regimens in the adjuvant breast cancer setting [17]. In line with
the enthusiastic embracement of the ‘‘dose-dense and/or sequen-
tial’’ concept in the design of randomized studies adopted by the
majority of collaborative groups, including ours, two randomized
phase III trials in patients with high-risk operable breast cancer
were designed and conducted sequentially by the Hellenic
Cooperative Oncology Group (HeCOG). In the first of these
trials (HE10/97) we compared dose-dense sequential chemother-
apy with epirubicin and CMF (cyclophosphamide, methotrexate
and 5-fluorouracil), with or without paclitaxel [18]. We did not
demonstrate a benefit in disease-free survival (DFS) or overall
survival (OS) between the two groups of patients, however the
study was not powered to identify a subtle but still biologically
meaningful difference. Conversely, the recently published Doc-
etaxel Epirubicin Adjuvant (DEVA) trial [19] has shown that the
substitution of docetaxel by epirubicin for the last three cycles of
treatment improved both DFS and OS in postmenopausal patients
with node-positive early breast cancer, compared to six cycles of
epirubicin monotherapy. In the second trial (HE10/00), concur-
rent administration of epirubicin and paclitaxel was compared
with dose-dense sequential administration of the drugs. Both
regimens were followed by dose-dense CMF [20,21]. No
difference was observed in DFS and OS between the two
treatment groups [21], however the concurrent arm had increased
toxicity [20]. Similarly, in the BCIRG-005 trial mentioned above
[11], the two regimens were equally effective but differed in their
toxicity profile, as well.
Of note, these randomized trials share with other similar trials a
major methodological and biological disadvantage in their design.
They simply include all patients fulfilling common clinico-
pathological criteria and breast cancer is treated as a single
clinical entity. However, during the past decade, DNA-microarray
studies have identified five molecularly discrete subtypes of breast
cancer, with different response to chemotherapeutic agents and
distinct prognosis [22,23]. These seminal studies, even though
small in size, clearly showed the path that clinicians had to follow
to successfully deal with breast cancer heterogeneity, using
molecular tools for treatment decisions. Nevertheless, these high-
throughput technology assays are not easy to be applied in large
trials mainly because they are costly and require fresh tumor tissue
that is not available in most studies.
To overcome these hurdles, investigators have recently been
using formalin-fixed paraffin-embedded (FFPE) tumor tissue to
immunohistochemically define breast cancer subtypes, which
markedly resemble those defined by gene expression analysis
and are at least as accurate and definitely more feasible.
Consequently, four biological markers assessed by immunohisto-
chemistry (IHC), i.e. estrogen receptor (ER), progesterone receptor
(PgR), HER2 and the cell proliferation marker Ki67 can classify
breast cancer in five subtypes: luminal A (ER-positive and/or
PgR-positive, HER2-negative and Ki67
low), luminal B (ER-
positive and/or PgR-positive, HER2-negative and Ki67
high),
luminal-HER2 (ER-positive and/or PgR-positive and HER2-
positive), HER2-enriched (ER-negative, PgR-negative, HER2-
positive) and triple-negative (ER-negative, PgR-negative, HER2-
negative) [24]. Furthermore, with the use of two additional
biological markers, cytokeratin 5 (CK5) and epidermal growth
factor receptor (EGFR), triple-negative breast cancer (TNBC)
tumors can be separated in two distinct subgroups, basal core
phenotype (BCP) and non-basal core phenotype (non-BCP) triple-
negative tumors.
Information regarding therapeutic response of breast cancer
subtypes to dose-dense adjuvant chemotherapy is very limited.
Therefore, in order to shed light on this issue we performed a
pooled analysis of the two previously mentioned randomized
HeCOG studies (HE10/97, HE10/00) [18,20,21] to evaluate the
outcome of patients treated with dose-dense chemotherapy
according to immunophenotypical subtypes. Individual patient
data from the two studies were combined, since they were both
dealing with the concepts of dose-dense and sequential chemo-
therapy administration, they used similar eligibility criteria for
patient participation and shared an identical chemotherapy arm.
Materials and Methods
Clinical studies
The HE10/97 trial [18] was a randomized phase III trial in
patients with high-risk node-negative or intermediate/high-risk
node-positive operable breast cancer, comparing four cycles of
epirubicin (E) followed by four cycles of intensified CMF (E-CMF)
with three cycles of E, followed by three cycles of paclitaxel (T,
TaxolH, Bristol Myers-Squibb, Princeton, NJ) followed by three
cycles of intensified CMF (E-T-CMF). All cycles were given every
two weeks with G-CSF support. Dose intensity of all drugs in both
treatment arms was identical, but cumulative doses and duration
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entered the study in a period of 3.5 years (1997–2000).
The HE10/00 trial [20,21] was a randomized phase III trial, in
which a total of 1,086 eligible patients with node-positive operable
breast cancer were accrued in a period of 5 years (2000–2005).
Patients were treated with E-T-CMF (exactly as in the HE10/97
trial) or with four cycles of epirubicin/paclitaxel (ET) combination
(given on the same day) every three weeks followed by three cycles
of intensified CMF every two weeks (ET-CMF). By study design,
the cumulative doses and the duration of chemotherapy period
were identical in the two arms but dose intensity of epirubicin and
paclitaxel was double in the E-T-CMF arm.
Treatment schedules for the two studies are described in detail
in Table S1. HER2-positive patients received trastuzumab upon
relapse, as previously described [25]. Baseline characteristics and
clinical outcomes of both trials have been published [18,20,21].
Primary tumor diameter, axillary nodal status and tumor grade
were obtained from the pathology report. Clinical protocols were
approved by local regulatory authorities and were also included in
the Australian New Zealand Clinical Trials Registry (ANZCTR)
and allocated the following Registration Numbers: ACTRN-
12611000506998 (HE10/97) and ACTRN12609001036202
(HE10/00). The present translational research protocol was
approved by the Bioethics Committee of the Aristotle University
of Thessaloniki School of Medicine under the general title
‘‘Molecular investigation of the predictive and/or prognostic role
of important signal transduction pathways in breast cancer’’
(A7150/18-3-2008). All patients signed a study-specific written
informed consent before randomization, which in addition to
giving consent for the trial allowed the use of their biological
material for future research purposes.
Tissue microarray (TMA) construction
FFPE tumor tissue samples (paraffin blocks) were collected
retrospectively in the first trial (HE10/97) and prospectively in the
second (HE10/00). The REMARK diagram [26] for the study is
shown in Figure 1. Representative hematoxylin-eosin stained
sections from the tissue blocks were reviewed by two experienced
in breast cancer pathologists (M.B. and D.T.) and the most
representative tumor areas were marked for the construction of the
TMA blocks with the use of a manual arrayer (Model I, Beecher
Instruments, San Prairie, WI), as previously described [27,28].
Each case was represented by 2 tissue cores, 1.5 mm in diameter,
obtained from the most representative tumor areas of primary
invasive or in some cases (9.6%) metastatic breast carcinomas and
re-embedded in 51 microarray blocks. Each TMA block contained
38 to 66 tissue cores from the original tumor tissue blocks, while
cores from various neoplastic, non-neoplastic and reactive tissues
were also included, serving as assay controls. Cases not represent-
ed, damaged or inadequate on the TMA sections were re-cut from
the original blocks and these sections were used for protein and
gene analysis.
Immunohistochemistry (IHC)
IHC for ER, PgR, HER2, Ki67, CK5 and EGFR was
performed on serial 2.5 mm thick sections, using the Bond Max
TM
and Bond III
TM autostainers (Leica Microsystems, Wetzlar,
Germany), as previously described in detail [29]. The immuno-
histochemical target proteins, the source and dilution of antibodies
used and the staining procedures for each target protein are
presented in Table 1. To assure optimal immunoreactivity, the
sections of the TMA blocks were stained in one run for each
antibody, at the Laboratory of Molecular Oncology of the
Hellenic Foundation for Cancer Research, Aristotle University
of Thessaloniki School of Medicine. All cases were also stained for
vimentin and cytokeratin 8/18, which were used as control stains
for tissue immunoreactivity and fixation, as well as identification of
tumor cells. Tissue samples negative for the above antibodies were
excluded from the study. The evaluation of all IHC sections was
done by experienced in breast cancer pathologists, blinded as to
the patients’ clinical characteristics and survival data.
Figure 1. REMARK diagram.
doi:10.1371/journal.pone.0037946.g001
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ER, PgR, HER2, Ki67, CK5 and EGFR protein expression was
evaluated in both tissue cores, according to the established or
proposed criteria [30–34] presented in Table 1. The mean
percentage of stained cells from the two cores was calculated by
two independent pathologists. In cases with different intensities,
the higher intensity score obtained from the two cores was used. If
one of the tissue cores was lost or damaged the overall score was
determined from the remaining one. When whole tissue sections
were used, the entire tumor area was evaluated.
Fluorescence in situ hybridization (FISH)
TMA sections or whole tissue sections (5 mm thick) were used
for FISH analysis of HER2, using the ZytoLight
H SPEC HER2/
TOP2A/CEN17 triple color probe (ZytoVision, Bremerhaven,
Germany), as previously described [35]. Four carcinoma cell lines
(MDA-MB-231, MDA-MB-175, MDA-MB-453, and SK-BR-3)
from the Oracle HER2 Control Slide (Leica Biosystems), with a
known HER2 gene status, were also used as a control of the FISH
assays and analyzed for HER2 genomic status. TOP2A gene
amplification was not evaluated for the purposes of the present
study, since this marker is not used for breast cancer subtyping.
For the evaluation of the HER2 gene status, non-overlapping
nuclei from the invasive part of the tumor were randomly selected
and scored. The virtual slides of HER2, ER or PgR stains, created
as previously described [36], were used for selecting the invasive
part of the tumor in each TMA. Twenty tumor nuclei were
counted according to Press et al [37]. The HER2 gene was
considered to be amplified when the ratio of the gene probe/
centromere probe was $2.2 [34], or the HER2 copy number was
.6 [38]. In cases with values at or near the cut-off (1.8–2.2),
additional 20 or 40 nuclei were counted and the ratio was
recalculated. In cases with a borderline ratio at 60 nuclei,
additional FISH assays were performed in whole sections. HER2
status was considered to be positive if HER2 was amplified (ratio
$2.2 or copy number .6) by FISH and/or a HER2 score of 3+
was obtained by IHC.
Statistical Analysis
Categorical data are presented as frequencies and correspond-
ing percentages, while continuous data are presented as median
and range values. The Fisher’s exact or Pearson chi-square tests
were used for group comparison of categorical data, while for
continuous data the non-parametric Mann-Whitney or the
Kruskall Wallis tests were used where appropriate. DFS was
measured from the date of randomization until recurrence of
tumor or secondary neoplasm or death from any cause [39]. OS
was measured from the date of randomization until death from
any cause. Surviving patients were censored at the date of last
contact. Time from relapse to death was also estimated. Time-to-
event distributions were presented using Kaplan-Meier curves.
Univariate Cox regression analyses were performed to assess the
relationship of breast cancer subtype classification with OS or
DFS. A backward selection procedure with a removal criterion of
p.0.10 was performed in the multivariate Cox regression analysis
in order to identify significant factors among age, paclitaxel
treatment (yes vs. no), involved axillary lymph nodes ($4 vs. 0–3),
tumor grade (III-Undifferentiated vs. I–II), tumor size (.5 cm; 2–
5 cm vs. #2 cm), type of surgery (yes vs. no), histology type
(invasive lobular; mixed; other vs. invasive ductal), adjuvant
hormonotherapy/radiotherapy (yes; missing vs. no) and breast
cancer subtype classification (luminal B; luminal-HER2; HER2-
enriched; TNBC vs. luminal A).
Results of this study were presented according to reporting
recommendations for tumor marker prognostic studies [26]. In the
present analysis, DFS and OS data were updated on March 2012.
All statistical tests were two sided, and p,0.05 was considered
statistically significant. The statistical analysis was conducted using
SPSS (SPSS for Windows, version 15.0, SPSS Inc.).
Results
A total of 1,039 patients with available FFPE tumor tissue blocks
were included in the analysis. Selected patient and tumor
characteristics according to treatment group (E-T-CMF vs E-
CMF vs ET-CMF), paclitaxel or non-paclitaxel-containing regi-
mens and clinical trial are depicted in Tables S2, S3 and S4,
respectively. Of note, there were significant differences in a
number of important tumor characteristics among patients with
and without blocks available. Patients with available blocks
presented with higher frequency of $4 positive nodes (both trials)
and tumor size .2 cm, adjuvant RT and grade 3 tumors (HE10/
00 trial), which might have contributed to an extent to the
increased availability of tissue blocks for research purposes in these
patients (Table S5). Importantly, no differences were detected for
DFS and OS between patients with or without available blocks.
Patients were classified, according to the 6 biological markers
assessed, as luminal A (ER-positive and/or PgR-positive, HER2-
negative and Ki67
low), luminal B (ER-positive and/or PgR-
positive, HER2-negative and Ki67
high), luminal-HER2 (ER-
positive and/or PgR-positive and HER2-positive), HER2-en-
riched (ER-negative, PgR-negative, HER2-positive), TNBC (ER-
negative, PgR-negative, HER2-negative) and BCP (TNBC, CK5-
positive and/or EGFR-positive). Basic clinico-pathological vari-
ables varied by breast cancer immunophenotypical sybtypes as
shown in Table 2. Grade 3 tumors comprised only about a quarter
of luminal A tumors, half of luminal B, and the majority of
luminal-HER2, HER2-enriched, TNBC and BCP tumors (56.3%,
76.4%, 69.2% and 75.2%, respectively). Invasive ductal histology
was found in over 80% of luminal-HER2, HER2-enriched, TNBC
and BCP tumors (85.9%, 88.2%, 80.5% and 81.2%, respectively).
In this cohort with worse pathological characteristics among the
high-risk patients entering an adjuvant chemotherapy trial, the age
distribution differed between subtypes. Tumors of the luminal-
HER2 subtype were more often encountered in younger (less than
50 year-old) patients, followed by luminal B and TNBC. Modified
radical mastectomy had been performed more frequently in
patients with HER2-enriched tumors, while adjuvant hormonal
therapy was given more often in patients with luminal tumors, as
would be expected. Of note, in the present analysis the subtypes
were defined following central assessment, while patients in both
trials were treated according to the evaluation of the ER and PgR
status at the local laboratories. The observed agreement for ER,
PgR and HER2 was 82.6%, 76.1% and 84.3%, respectively, with
a kappa of 58.1%, 48.0% and 61.6%, respectively.
After a median follow-up time of 105.4 months (range, 0.1–
166.7), 5-year and 10-year DFS rates for all patients in the study
were 73.1% and 60.3%, respectively. Likewise, 5-year and 10-year
OS rates were 86.1% and 70.6%, respectively. (Table S6).
Survival status and site of first relapse according to breast cancer
subtype is shown in Table 3. Locoregional relapses occurred more
frequently in patients with TNBC, while distant relapses were
more rare in patients with luminal A tumors compared to the
other subtypes. Notably, liver metastases were most often recorded
in patients with HER2-enriched tumors, while brain tumors in
patients with TNBC. Bone was the most frequent site of metastasis
in patients with luminal-HER2 and luminal B tumors. Finally,
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patients with luminal A tumors.
There were no significant differences in DFS or OS among
patients treated with the three different regimens (Figure S1). The
subtype classification was prognostic for both DFS and OS.
Setting luminal A as the referent category, we observed an
increased risk for relapse and death in all subtypes. The hazard
ratio (HR), 95% confidence interval (CI) and p value for each
subtype for DFS and OS are shown in Table 4. Within the TNBC
subtype, BCP tumors were associated with lower risk for relapse
compared to non-BCP tumors (Figure S2), however the number of
patients in the two subgroups is small for meaningful comparisons.
As presented in the survival plots (Figure 2), patients with
TNBC, luminal-HER2 and HER2-enriched tumors had, in the
pre-trastuzumab era for early disease, a high risk for relapse in the
first 5 to 6 years from initial diagnosis, while patients with
luminal A and B tumors had a lower but almost constant risk for
relapse across all years. Concerning OS, again patients with
TNBC had an increased risk for death in the first 4 to 5 years,
while patients with luminal-HER2 and HER2-enriched tumors,
despite similar relapse rates, showed a much lower risk for death
compared to TNBC patients, probably reflecting the beneficial
effect of trastuzumab given at relapse in most cases [25].
Among patients with relapse (n=311), 70.4% died. The median
time from relapse to death was significantly shorter for TNBC
patients (median=16.7, 95% CI: 12.3–21.1 months), compared to
the luminal A (median=44.8, 95% CI: 23.1–66.5 months,
p,0.001), luminal B (median=33.2, 95% CI: 28.3–38.1 months,
p=0.006), luminal-HER2 (median=43.0, 95% CI: 30.3–55.7
months, p=0.006) and HER2-enriched (median=35.4, 95% CI:
28.1–42.8 months, p=0.011). When adjusting for treatment and
other prognostic factors, all subtypes had worse DFS and OS than
the luminal A subtype (Figure 3).
DFS and OS were compared in a predefined analysis between
taxane containing treatment arms (E-T-CMF and ET-CMF) and
the non-taxane containing treatment (E-CMF), in each IHC-
defined subtype group. A significant benefit from paclitaxel
containing regimens for both DFS and OS (log-rank, p=0.021
and p=0.006, respectively) was noticed among patients with
HER2-enriched tumors (Figure 4).
In the multivariate analysis (Figure 3), apart from any subtype
compared to luminal A, higher tumor size, and $4 positive nodes
were adverse prognostic factors for both DFS and OS, with
modified radical mastectomy (MRM) surgery being an adverse
prognostic factor for DFS and absence of hormonal therapy for
OS. Adjusting for the prognostic factors, a significant benefit from
the taxane containing treatment was found in the HER2-enriched
subtype, with estimated HR=0.44 (95% CI: 0.20–0.98; interac-
tion p=0.037) and HR=0.32 (95% CI: 0.13–0.78; interaction
p=0.014), for DFS and OS, respectively. Treatment with taxanes
was not associated with DFS or OS in the luminal A, luminal B,
luminal-HER2 and TNBC subtypes.
Table 3. Survival status according to breast cancer subtypes defined by immunohistochemistry (for subtype description see
Table 2 legend).
Luminal A
(N=258)
Luminal B
(N=396)
Luminal-HER2
(N=142)
HER2-enriched
(N=110)
TNBC
(N=133)
BCP*
(N=101)
Disease-free survival
Progressions N (%) 48 (18.6) 122 (30.8) 52 (36.6) 39 (35.5) 50 (37.6) 35 (34.7)
Events N (%) 66 (25.6) 152 (38.4) 60 (42.3) 40 (36.4) 59 (44.4) 40 (39.6)
5-year rate (%) 83.5 75.7 64.0 67.0 60.6 64.4
10-year rate (%) 66.6 58.1 56.1 63.2 56.2 59.5
Range 6.0–121.5 4.0–160.5 5.3–109.3 5.1–77.0 6.9–143.0 9.6–89.9
Overall survival
Deaths N (%) 39 (15.1) 111 (28.0) 46 (32.4) 27 (24.5) 52 (39.1) 35 (34.7)
5-year rate (%) 92.1% 88.2% 85.8% 83.3% 70.5% 73.3
10-year rate (%) 79.4% 69.8% 62.6% 72.1% 61.7% 65.6
Range 25.7–143.4 4.3–160.5 10.5–120.6 13.0–110.9 8.1–151.3 13.6–151.3
Relapses N (%)
Locoregional relapse
1 6 (2.3) 16 (4.0) 7 (4.9) 9 (8.2) 14 (10.5) 12 (11.9)
Distant relapse
2 44 (17.1) 114 (28.8) 42 (29.6) 35 (31.8) 41 (30.8) 26 (25.7)
Brain
3 2 (0.8) 8 (2.0) 2 (1.4) 1 (0.9) 8 (6.0) 6 (5.9)
Lung 15 (5.8) 34 (8.6) 13 (9.2) 14 (12.7) 15 (11.3) 9 (8.9)
Liver
4 12 (4.7) 33 (8.3) 11 (7.7) 18 (16.4) 7 (5.3) 3 (3.0)
Bones
5 21 (8.1) 60 (15.2) 22 (15.5) 9 (8.2) 14 (10.5) 7 (6.9)
Soft tissue/nodes 5 (1.9) 16 (4.0) 5 (3.5) 6 (5.5) 7 (5.3) 7 (6.9)
Visceral
6 26 (10.1) 66 (16.7) 25 (17.6) 29 (26.4) 28 (21.1) 18 (17.8)
Locoregional & distant 3 (1.2) 8 (2.0) 1 (0.7) 5 (4.5) 4 (3.0) 3 (3.0)
*BCP =75.9% of TNBC.
BCP, basal core phenotype; N, number; TNBC, triple-negative breast cancer.
1p=0.005;
2p=0.003;
3p=0.023;
4p=0.006;
5p=0.03;
6p=0.001.
doi:10.1371/journal.pone.0037946.t003
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In the present study we investigated the clinical outcome of
patients with operable breast cancer classified to five well-
established immunophenotypical breast cancer subtypes. These
patients were included in two consecutively conducted adjuvant
phase III trials with dose-dense sequential chemotherapy
[18,20,21]. The five subtypes were defined with the use of a
four-marker panel (ER, PgR, HER2 and Ki67), as also reported
by others [24]. Notably, with the use of two additional biological
markers, CK5 and EGFR we further separated triple negative
tumors into two distinct subgroups, BCP and non-BCP.
The largest group of patients in our study was of the luminal B
subtype (38.1%) followed by luminal A (24.8%). In contrast to the
corresponding rate in large registry data sets, hospital-based or
population-based case series [40–42], in which luminal B tumors
represented only a small minority, about half of the tumors in our
study were classified as luminal B/luminal-HER2. This is in
keeping with the existing literature, for an ‘‘intermediate or high-
risk’’ population entering a randomized trial with adjuvant
chemotherapy in operable breast cancer [43,44]. Conceivably,
patients with more favorable prognosis, like those with luminal A
tumors, are usually treated with less aggressive chemotherapeutic
regimens followed by hormonal therapy or even with hormonal
therapy alone.
Our study has several strengths, as well as limitations. It has
been postulated that breast cancer subtypes are predictive and
behave differently to specific treatments [40]. If so, response
evaluation of these subtypes to modern chemotherapeutic
regimens, in the context of randomized trials, is of great
importance. In our study, tissue blocks were obtained from
patients participating in two such trials, investigating the role of
epirubicin, paclitaxel and CMF-containing dose-dense sequential
chemotherapy, which shared similar eligibility criteria. Further-
more, all IHC and in situ hybridization testing was carried out in a
central ‘‘high-volume’’ laboratory, negating inter-laboratory assay
result variability and, in parallel, scoring was done by experienced
pathologists. Therefore, the possibility for misclassification of
tumors was significantly reduced.
On the other hand, tumor tissue blocks were retrospectively
collected in the HE10/97 trial and prospectively in the HE10/00
trial. Therefore, in the present analysis, patients with available
blocks may not be representative of the entire patient population
enrolled in the two trials, since there were differences in tumor
size, number of metastatic lymph nodes and tumor grade, which
may lead to biases. Nevertheless, these variables were taken into
account in the multivariate analyses. Furthermore, the size of both
trials is considered to be intermediate according to current
standards, which may preclude the identification of subtle but still
biologically meaningful differences in prognosis, especially in
subtypes with relatively small number of patients, i.e. BCP or non-
BCP TNBC subtypes, if examined separately.
Since a considerable number of patients in the present analysis
were not treated with paclitaxel, while all received epirubicin and
CMF, we sought for potentially differential responses of the
Table 4. Univariate Cox regression analysis for breast cancer subtypes (for subtype description see Table 2 legend).
DFS OS
Hazard Ratio 95% CI Wald’s p value Hazard Ratio 95% CI Wald’s p value
Luminal B vs. Luminal A 1.54 1.15–2.06 0.003 1.83 1.27–2.63 0.001
Luminal-HER2 vs. Luminal A 1.87 1.32–2.65 ,0.001 2.21 1.44–3.39 ,0.001
HER2-enriched vs. Luminal A 1.61 1.07–2.38 0.018 1.70 1.04–2.78 0.034
TNBC vs. Luminal A 2.10 1.48–2.98 ,0.001 3.05 2.02–4.63 ,0.001
DFS, disease-free survival; OS, overall survival; CI, confidence interval; TNBC, triple-negative breast cancer.
doi:10.1371/journal.pone.0037946.t004
Figure 2. DFS and OS according to breast cancer subtypes. Patients were classified as: luminal A (ER-positive and/or PgR-positive, HER2-
negative, Ki67
low); luminal B (ER-positive and/or PgR-positive, HER2-negative, Ki67
high); luminal-HER2 (ER-positive and/or PgR-positive, HER2-positive);
HER2-enriched (ER-negative, PgR-negative, HER2-positive); and triple-negative (TNBC) (ER-negative, PgR-negative, HER2-negative).
doi:10.1371/journal.pone.0037946.g002
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demonstrate a particular benefit from the use of paclitaxel only in
patients with HER2-enriched tumors. In a previously published
study on FFPE tissue samples from 394 patients randomized in the
HE10/97 trial, an association of HER2 status and outcome was
not detected, maybe due to the smaller sample size and HER2
status classification based mainly on IHC [45]. However, in a large
retrospective analysis of 1,322 FFPE tissue blocks from 3,121
women participating in the Cancer and Leukemia Group B
93441/INT0148 trial (four cycles of doxorubicin and cyclophos-
phamide followed by four cycles of paclitaxel or observation),
Hayes et al [46] reported that a survival benefit from the addition
of paclitaxel was evident in patients with HER2-positive tumors
regardless of ER status.
Regarding the behavior of TNBC patients in response to
treatment with taxanes, results in the literature are equivocal at
best. An analysis of the Groupo Espanol de Investigacion en
Cancer de Mama (GEICAM) 9906 trial has shown a superiority of
the fluorouracil, epirubicin, cyclophosphamide (FEC) combination
followed by weekly paclitaxel over FEC alone, which was more
prominent in patients with TNBC [44]. In line with these data,
Iwata et al [47] reported that patients with TNBC were more
likely to achieve pathological complete response (pCR) to
neoadjuvant chemotherapy with four cycles of docetaxel followed
by four cycles of FEC compared to those with other subtypes.
Conversely, in the Breast Cancer International Research Group
(BCIRG)-001 trial the combination of docetaxel (TaxotereH),
doxorubicin (AdriamycinH) and cyclophosphamide (TAC) offered
Figure 3. Forest plots from multivariate Cox regression models: DFS (a) and OS (b) (for subtype description see Figure 2 legend).
doi:10.1371/journal.pone.0037946.g003
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e37946a significant improvement in 3-year DFS in patients with
luminal B (defined as ER-positive, PgR-positive and either
Ki67
high or HER-positive), but only a marginal trend in patients
with TNBC or HER2-enriched tumors over treatment with
fluorouracil, doxorubicin, cyclophosphamide (FAC). Intriguingly,
among patients with node-positive operable breast cancer
randomized in the PACS01 trial comparing six cycles of adjuvant
FEC with three cycles of FEC followed by three cycles of docetaxel
[48], those with luminal A did not benefit from docetaxel.
Conversely, patients with luminal B, HER2-overexpressing and
triple negative tumors had a significant reduction in their risk for
relapse. Ki67 positivity was the most powerful predictor of benefit
from docetaxel [49]. We were not able to show a paclitaxel benefit
in patients with TNBC. Whether this is due to differences in
sample size, regimens used, patient populations or other uniden-
tified factors cannot be revealed by the present analysis.
It has been shown that the pattern of first relapse varies among
patients with different breast cancer subtypes [50]. That was also
the case for the randomized patients analyzed in our study, in
which locoregional relapses as well distant relapses were more
frequently seen in patients with TNBC and HER2-enriched
tumors, a finding that has been also observed by others in hospital-
based case series [24,51]. The 6% rate of brain metastases,
recorded in our patients with TNBC at the 5-year time point, was
almost identical to that reported in other large studies [51–53]. It is
worth mentioning that HER2 is considered to be a robust risk
factor for the development of CNS disease [54,55]. A retrospective
analysis of 9,524 patients enrolled in 10 adjuvant trials, led by the
International Breast Cancer Study Group in the pre-trastuzumab
era, reported that the 10-year cumulative incidence of brain as
primary site of metastasis was 2.7% in patients with HER2-
positive tumors and 1.0% in patients with HER2-negative tumors
(p,0.01) [56]. The respective rate in our patients with HER2-
positive disease was slightly above 1%. Finally, the present analysis
confirmed the significant liver predisposition of metastases
associated with HER2-enriched tumors reported by others
[24,41].
Notable differences in the behavior of breast cancer subtypes
are not seen only in the pattern of metastases, but also in the time
to first relapse. Data from 498 patients, enrolled in a randomized
trial exploring the beneficial role of local cavity boost of RT to
breast conserving therapy, indicated that median time to first
event was significantly shorter for TNBC and HER2-enriched
subtypes. Crude recurrence rates of luminal A tumors were less
than one third of those seen in BCP tumors, regarding loco-
regional relapses, and less than half regarding the development of
distant metastases at 5 years [50]. In the study by Blows [40],
which pooled individual data from more than 10,000 patients with
invasive breast cancer from 12 studies with known status of ER,
HER2 and at least one basal marker (CK5/6 or EGFR), it was
clearly shown that even though for HER2-positive and non-
luminal subtypes mortality rates tended to peak within 5 years
from diagnosis, with longer follow-up the prognosis became poorer
in the luminal subtypes. Unfortunately, in that study, information
on Ki67 status was not available and this might have led to
misclassification of patients with luminal B as luminal A. These
data fit perfectly with the cumulative hazard plots extracted from
the present analysis, with patients with TNBC and HER2-positive
tumors having an increased risk for relapse and death in the first 5
to 6 years from initial diagnosis. On the contrary, patients with
luminal tumors had a constant risk for relapse and death across
time. Further, at 5 years, the DFS and OS rates for patients with
luminal A tumors were 83.5% and 92.1%, while for those with
TNBC were 60.6% and 70.5%, respectively.
In summary, the present pooled analysis of individual data of
more than 1,000 patients with ‘‘intermediate or high-risk’’
operable breast cancer, according to the immunophenotypical
subtypes of their tumor, indicated that in the presence of dose-
dense chemotherapy, patients with TNBC have the worse
prognosis and luminal A the best. For patients with HER2-
positive disease, a similar pattern emerges up to recurrence, in the
adjuvant pre-trastuzumab era, while prolongation of time from
recurrence to survival is noted, probably because of the use of
trastuzumab. A predictive role of the subtypes for benefit from
paclitaxel was not identified, except for patients with HER2-
enriched tumors. Clearly, more data, similar to those reported
here, from other randomized trials and eventually a meta-analysis,
would be needed to delineate the predictive value of each subtype
and especially of TNBC, for which a complementary targeted
treatment to dose-dense sequential chemotherapy does not
presently exist.
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